LLY

745.65

-5.07%↓

UNH

591.87

-0.26%↓

NVO

101.73

-3.45%↓

ABBV

164.93

-2.74%↓

MRK

96.19

-2.24%↓

LLY

745.65

-5.07%↓

UNH

591.87

-0.26%↓

NVO

101.73

-3.45%↓

ABBV

164.93

-2.74%↓

MRK

96.19

-2.24%↓

LLY

745.65

-5.07%↓

UNH

591.87

-0.26%↓

NVO

101.73

-3.45%↓

ABBV

164.93

-2.74%↓

MRK

96.19

-2.24%↓

LLY

745.65

-5.07%↓

UNH

591.87

-0.26%↓

NVO

101.73

-3.45%↓

ABBV

164.93

-2.74%↓

MRK

96.19

-2.24%↓

LLY

745.65

-5.07%↓

UNH

591.87

-0.26%↓

NVO

101.73

-3.45%↓

ABBV

164.93

-2.74%↓

MRK

96.19

-2.24%↓

Search

Johnson and Johnson

Cerrado

Sector Salud

153.97 1.41

Resumen

Variación precio

24h

Actual

Mínimo

153.75

Máximo

154.32

Métricas clave

By Trading Economics

Ingresos

-2B

2.7B

Ventas

50M

23B

P/B

Media del Sector

24.52

104.138

BPA

2.42

Margen de beneficio

11.973

Empleados

131,900

EBITDA

-2.4B

5.4B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+15.64 upside

Dividendos

By Dow Jones

Próximas Ganancias

21 ene 2025

Fecha Próximo Dividendo

10 dic 2024

Próxima Fecha de Ex Dividendo

26 nov 2024

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

1.1B

387B

Apertura anterior

152.56

Cierre anterior

153.97

Noticias sobre sentimiento de mercado

By Acuity

24%

76%

50 / 392 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Johnson and Johnson Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

28 oct 2024, 16:07 UTC

Adquisiciones, fusiones, absorciones

AbbVie to Acquire Aliada Therapeutics for $1.4 Billion -- Update

15 oct 2024, 19:26 UTC

Ganancias

Trending: Johnson & Johnson Posts Higher-Than-Expected Sales

12 nov 2024, 20:04 UTC

Principales Noticias

J&J Sues U.S. Over Hospital Drug-Discounting Program -- WSJ

21 oct 2024, 15:26 UTC

Adquisiciones, fusiones, absorciones

Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies -- IBD

21 oct 2024, 09:51 UTC

Principales Noticias

Starboard Targets Another Health Company. Why Kenvue Is in Its Sights. -- Barrons.com

21 oct 2024, 09:30 UTC

Principales Noticias

J&J's Ketamine-Derived Drug Is Taking Off -- WSJ

15 oct 2024, 12:09 UTC

Principales Noticias
Ganancias

J&J Reports Strong Earnings but Talc Worries Remain. The Stock Falls. -- Barrons.com

15 oct 2024, 12:04 UTC

Ganancias

Johnson & Johnson Earnings Top; Dow Giant Falls Amid Lowered Outlook -- IBD

15 oct 2024, 11:52 UTC

Principales Noticias
Ganancias

J&J Reports Strong Earnings but Talc Worries Remain. The Stock Falls. -- Barrons.com

15 oct 2024, 10:50 UTC

Ganancias

Johnson & Johnson Stock Rises On Q3 Sales Beat And Guidance Raise -- MarketWatch

15 oct 2024, 10:28 UTC

Principales Noticias
Ganancias

J&J Reports Strong Earnings but Talc Worries Remain. The Stock Rises. -- Barrons.com

15 oct 2024, 10:25 UTC

Ganancias

J&J Reports Strong Earnings but Talc Worries Remain -- Barrons.com

15 oct 2024, 10:20 UTC

Ganancias

J&J Earnings Beat Expectations, Aided by Prescription-Drug Sales -- WSJ

15 oct 2024, 10:20 UTC

Ganancias

Johnson & Johnson Cuts 2024 View To Adj EPS $9.88-Adj EPS $9.98 Vs Prior View $9.97-$10.07 >JNJ

15 oct 2024, 10:20 UTC

Ganancias

Johnson & Johnson Cuts 2024 Adjusted Operational EPS View to $9.86-$9.96 Vs Prior View $10.00-$10.10 >JNJ

15 oct 2024, 10:20 UTC

Ganancias

Johnson & Johnson Raises 2024 Adjusted Operational Sales Growth View to 5.7%-6.2% From Prior View 5.5%-6%>JNJ

15 oct 2024, 10:20 UTC

Ganancias

Johnson & Johnson Updates 2024 Guidance to Reflect Improved Perfromance and Impact From Recent Acquisition of V-Wave >JNJ

15 oct 2024, 10:20 UTC

Ganancias

Johnson & Johnson 3Q U.S. Sales $12.91B >JNJ

15 oct 2024, 10:20 UTC

Ganancias

Johnson & Johnson Raises 2024 Operational Sales View to $89.4B-$89.8B Vs Prior View $89.2B-$89.6B >JNJ

15 oct 2024, 10:20 UTC

Ganancias

Johnson & Johnson: MedTech Business, With Addition of Shockwave Medical, Delivered Operational Sales Growth of 6.4% in 3Q >JNJ

15 oct 2024, 10:20 UTC

Ganancias

Johnson & Johnson Raises 2024 View To Sales $88.4B-$88.8B Vs Prior View $88.0B-$88.4B >JNJ

15 oct 2024, 10:20 UTC

Ganancias

Johnson & Johnson 3Q Adj EPS $2.42 >JNJ

15 oct 2024, 10:20 UTC

Ganancias

Johnson & Johnson: Innovative Medicine 3Q Results Driven by Key Brands Such as DARZALEX, ERLEADA, TREMFYA and SPRAVATO and Continued Uptake From Recently Launched Products Including CARVYKTI, RYBREVANT, TECVAYLI and TALVEY, With 11 Assets Delivering Double-Digit Growth >JNJ

15 oct 2024, 10:20 UTC

Ganancias

Johnson & Johnson 3Q Orthopaedics Sales $2.19B >JNJ

15 oct 2024, 10:20 UTC

Ganancias

Johnson & Johnson 3Q International Sales $9.56B >JNJ

15 oct 2024, 10:20 UTC

Ganancias

Johnson & Johnson 3Q Worldwide MedTech Sales $7.89B >JNJ

15 oct 2024, 10:20 UTC

Ganancias

Johnson & Johnson 3Q Worldwide Innovative Medicine Sales $14.58B >JNJ

15 oct 2024, 10:20 UTC

Ganancias

Johnson & Johnson 3Q Sales $22.47B >JNJ

15 oct 2024, 10:20 UTC

Ganancias

Johnson & Johnson 3Q EPS $1.11 >JNJ

15 oct 2024, 10:20 UTC

Ganancias

Johnson & Johnson 3Q Worldwide MedTech Sales $7.89B >JNJ

Comparación entre iguales

Cambio de precio

Johnson and Johnson Esperado

Precio Objetivo

By TipRanks

15.64% repunte

Estimación a 12 meses

Media 178.08 USD  15.64%

Máximo 215 USD

Mínimo 159 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Johnson and Johnson Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

14 ratings

6

Comprar

8

Mantener

0

Vender

Puntuación técnica

By Trading Central

153.24 / 155.41Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

50 / 392 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Johnson and Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.